World Human Organoids (Pancreas, Kidney, Lung, GIT, Liver Models) Market Report 2020 – ResearchAndMarkets.com
December 30, 2020DUBLIN–(BUSINESS WIRE)–The “Human Organoids Market Report” report has been added to ResearchAndMarkets.com’s offering.
The global human organoids market size is projected to reach USD 1,901 million by 2025 from USD 850 million in 2020, at a CAGR of 17.5%.
Factors such as the technological advancements in the market are propelling the growth of the human organoids market. Additionally, rising cases of transplants, investments from both private and public sectors are having affect in the growth of human organoids market. However, unfavorable reimbursement scenarios in some countries is hampering the growth of this market.
The recent COVID-19 global pandemic has also impacted the human organoids market. Demand from the main end-users has declined as key regions and countries have imposed social distancing rules and lockdowns. This impact is expected to be short-term, and no adverse effects are to be foreseen after the market gradually reopens.
“The kidney segment to witness the highest growth rate in human organoids market, by product, during the forecast period.”
The kidney segment is expected to witness the highest growth rate during the forecast period. The high growth in this owes to the high prevalence of kidney diseases across major markets (resulting in a growing number of transplants procedures), the growing trend of increasing purchasing power of people, especially across emerging countries.
“The developmental biology accounted for the largest share of the human organoids market, by human organoids, in 2020. (Read more…)”
The developmental biology segment accounted for the largest share of the human organoids market in 2020. Technological advancements in the field of 3D bioprinting have shown huge potential for organ development as the culture time is very less compared to traditional methods of tissue culture. Patient-derived human organoid studies may accelerate medical research, creating new opportunities for tissue engineering and regenerative medicine and generating knowledge and tools for preclinical studies, including drug development and testing.
“The pharmaceuticals & biotechnology companies segment accounted for the largest share of the human organoids, by end users, in 2020”
Pharmaceutical and biotechnology companies mainly focus on developing new drugs for the treatment of various rare diseases. These companies need to submit specific data related to drug development during the drug development process and subsequent filing of applications to regulatory bodies. This necessitates a wide spectrum of services in the early development phases and clinical phases to comply with regulatory requirements.
“The Asia Pacific market to grow at the highest CAGR during the forecast period.”
The clinical microbiology market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Government efforts to increase awareness related to human orgnaoids, supportive regulations for the development and commercialization of advanced human organoids products, rising healthcare expenditure, increasing number of hospitals and clinics in India and China, expanding research base across India, China, and Japan, and the increasing incidence of transplants are the major factors driving the growth of the APAC human organoids market.
The major players operating in the human organoids market are BioIVT (US), Thermo Fisher Scientific (US), ZenBio (US), Corning (US), Organovo (US), Cyprio (France), Biopredic International (France), CELLINK (Sweden), Emulate (US), Hrel Corporation (US), InSphero (Switzerland), Kerafast (US), Kirkstall (UK), and MIMETAS (Netherlands).
Market Dynamics
Drivers
- Growing Focus on Developing Alternatives for Animal Testing Models
- Significant Increase in Research Funding and Venture Capital Investments for the Development of Human Organoids
- Growing Initiatives to Increase Awareness About Organoids
- Increasing Research Activities on Organoids
- Increasing Prevalence of Non-Alcoholic Fatty Liver Disease
- Growing Need for the Early Detection of Drug Toxicity to Minimize Financial Losses Due to Late-Stage Drug Failure
Restraints
- Issues Related to the Incorporation of Organoids into Existing Workflows
Opportunities
- Increasing Focus on Drug Discovery Activities
- Rising Demand for Organ Transplantation
- Growing Healthcare Market in the Asia-Pacific and Latin America
Challenges
- Dearth of Skilled Professionals
Impact of the COVID-19 Pandemic on the Human Organoids Market
Regulatory Scenario
Ecosystem Coverage
Technology Analysis
Pricing Analysis
Companies Mentioned
- Bioivt
- Biopredic International
- Cellink
- CN Bio Innovations
- Corning Incorporated
- Cyprio
- Cytes Biotechnologies, S.L.
- Emerging Companies
- Emulate, Inc.
- Hurel Corporation
- Insphero
- Kaly-Cell
- Kerafast
- Kirkstall Ltd.
- Mimetas B.V.
- Neuromics
- Organovo
- Primacyt Cell Culture Technology Gmbh
- Stemcell Technologies Inc.
- Thermo Fisher Scientific
- Zenbio, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/tw1t9y
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
World Human Organoids (Pancreas, Kidney, Lung, GIT, Liver Models) Market Report 2020 – ResearchAndMarkets.com
December 30, 2020DUBLIN–(BUSINESS WIRE)–The “Human Organoids Market Report” report has been added to ResearchAndMarkets.com’s offering.
The global human organoids market size is projected to reach USD 1,901 million by 2025 from USD 850 million in 2020, at a CAGR of 17.5%.
Factors such as the technological advancements in the market are propelling the growth of the human organoids market. Additionally, rising cases of transplants, investments from both private and public sectors are having affect in the growth of human organoids market. However, unfavorable reimbursement scenarios in some countries is hampering the growth of this market.
The recent COVID-19 global pandemic has also impacted the human organoids market. Demand from the main end-users has declined as key regions and countries have imposed social distancing rules and lockdowns. This impact is expected to be short-term, and no adverse effects are to be foreseen after the market gradually reopens.
“The kidney segment to witness the highest growth rate in human organoids market, by product, during the forecast period.”
The kidney segment is expected to witness the highest growth rate during the forecast period. The high growth in this owes to the high prevalence of kidney diseases across major markets (resulting in a growing number of transplants procedures), the growing trend of increasing purchasing power of people, especially across emerging countries.
“The developmental biology accounted for the largest share of the human organoids market, by human organoids, in 2020. (Read more…)”
The developmental biology segment accounted for the largest share of the human organoids market in 2020. Technological advancements in the field of 3D bioprinting have shown huge potential for organ development as the culture time is very less compared to traditional methods of tissue culture. Patient-derived human organoid studies may accelerate medical research, creating new opportunities for tissue engineering and regenerative medicine and generating knowledge and tools for preclinical studies, including drug development and testing.
“The pharmaceuticals & biotechnology companies segment accounted for the largest share of the human organoids, by end users, in 2020”
Pharmaceutical and biotechnology companies mainly focus on developing new drugs for the treatment of various rare diseases. These companies need to submit specific data related to drug development during the drug development process and subsequent filing of applications to regulatory bodies. This necessitates a wide spectrum of services in the early development phases and clinical phases to comply with regulatory requirements.
“The Asia Pacific market to grow at the highest CAGR during the forecast period.”
The clinical microbiology market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Government efforts to increase awareness related to human orgnaoids, supportive regulations for the development and commercialization of advanced human organoids products, rising healthcare expenditure, increasing number of hospitals and clinics in India and China, expanding research base across India, China, and Japan, and the increasing incidence of transplants are the major factors driving the growth of the APAC human organoids market.
The major players operating in the human organoids market are BioIVT (US), Thermo Fisher Scientific (US), ZenBio (US), Corning (US), Organovo (US), Cyprio (France), Biopredic International (France), CELLINK (Sweden), Emulate (US), Hrel Corporation (US), InSphero (Switzerland), Kerafast (US), Kirkstall (UK), and MIMETAS (Netherlands).
Market Dynamics
Drivers
- Growing Focus on Developing Alternatives for Animal Testing Models
- Significant Increase in Research Funding and Venture Capital Investments for the Development of Human Organoids
- Growing Initiatives to Increase Awareness About Organoids
- Increasing Research Activities on Organoids
- Increasing Prevalence of Non-Alcoholic Fatty Liver Disease
- Growing Need for the Early Detection of Drug Toxicity to Minimize Financial Losses Due to Late-Stage Drug Failure
Restraints
- Issues Related to the Incorporation of Organoids into Existing Workflows
Opportunities
- Increasing Focus on Drug Discovery Activities
- Rising Demand for Organ Transplantation
- Growing Healthcare Market in the Asia-Pacific and Latin America
Challenges
- Dearth of Skilled Professionals
Impact of the COVID-19 Pandemic on the Human Organoids Market
Regulatory Scenario
Ecosystem Coverage
Technology Analysis
Pricing Analysis
Companies Mentioned
- Bioivt
- Biopredic International
- Cellink
- CN Bio Innovations
- Corning Incorporated
- Cyprio
- Cytes Biotechnologies, S.L.
- Emerging Companies
- Emulate, Inc.
- Hurel Corporation
- Insphero
- Kaly-Cell
- Kerafast
- Kirkstall Ltd.
- Mimetas B.V.
- Neuromics
- Organovo
- Primacyt Cell Culture Technology Gmbh
- Stemcell Technologies Inc.
- Thermo Fisher Scientific
- Zenbio, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/tw1t9y
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900